IsoRay Medical Inc. made official Wednesday its plan to test the feasibility of producing cancer-fighting medical isotopes at a federal reactor in Idaho.

Officials with Richland-based IsoRay joined officials with Idaho State University, the city of Pocatello and the U.S. Department of Energy's Idaho National Laboratory to announce the deal in Pocatello.

IsoRay is producing a new treatment product for prostate cancer, tiny radioactive seeds that are injected to release a targeted dose of radiation to kill cancer cells.

If the test is successful, IsoRay would be obligated to open a production facility in Pocatello or pay back $260,000 in test costs, Richard Girard, IsoRay chief executive, said in October.